These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10588772)

  • 1. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole.
    Richter J; Freise S; Mull R; Millán JC
    Trop Med Int Health; 1999 Nov; 4(11):774-81. PubMed ID: 10588772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.
    Millán JC; Mull R; Freise S; Richter J;
    Am J Trop Med Hyg; 2000; 63(5-6):264-9. PubMed ID: 11421375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasciola hepatica-a "Diver" in the Biliary Tree.
    Martins A; Gonçalves Á; Almeida T; Lopes L; Midões A
    J Gastrointest Surg; 2017 Nov; 21(11):1959-1960. PubMed ID: 28634648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentation and management of Fasciola hepatica infection: single-center experience.
    Kaya M; Beştaş R; Cetin S
    World J Gastroenterol; 2011 Nov; 17(44):4899-904. PubMed ID: 22171131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic imaging in the study of human hepatobiliary fascioliasis.
    Cantisani V; Cantisani C; Mortelé K; Pagliara E; D'Onofrio M; Fernandez M; D'Ambrosio U; Lombardi V; Marigliano C; Ricci P
    Radiol Med; 2010 Feb; 115(1):83-92. PubMed ID: 20012922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.
    Winkelhagen AJ; Mank T; de Vries PJ; Soetekouw R
    Emerg Infect Dis; 2012 Jun; 18(6):1028-9. PubMed ID: 22607719
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatic mass caused by Fasciola hepatica: a tricky differential diagnosis.
    Yilmaz B; Köklü S; Gedikoglu G
    Am J Trop Med Hyg; 2013 Dec; 89(6):1212-3. PubMed ID: 24080633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living Fasciola hepatica in biliary tree: a case report.
    Aminian K; Rezayat KA; Shafaghi A; Tanhaeevash R
    Ann Hepatol; 2012; 11(3):395-8. PubMed ID: 22481460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fasciola hepatica infection. Successful therapy using triclabendazole].
    Markwalder K; Koller M; Goebel N; Wolff K
    Schweiz Med Wochenschr; 1988 Jul; 118(27-28):1048-52. PubMed ID: 3413464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical presentation of a very rare infection: parenchymal Fasciola hepatica.
    Sapmaz F; Kalkan IH; Guliter S; Nazlıoğlu A
    Turkiye Parazitol Derg; 2013; 37(4):305-6. PubMed ID: 24412878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An incidental case of biliary fascioliasis mimicking cholangiocellular carcinoma.
    Şenateş E; Doğan A; Şenates BE; Bodakçi E; Bekçibasi M
    Infez Med; 2014 Dec; 22(4):313-6. PubMed ID: 25551848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case Series.
    Cabada MM; Lopez M; Cruz M; Delgado JR; Hill V; White AC
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004361. PubMed ID: 26808543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response.
    Apt W; Aguilera X; Vega F; Miranda C; Zulantay I; Perez C; Gabor M; Apt P
    Am J Trop Med Hyg; 1995 Jun; 52(6):532-5. PubMed ID: 7611560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary obstruction caused by the liver fluke, Fasciola hepatica.
    Ishikawa T; Meier-Stephenson V; Heitman SJ
    CMAJ; 2016 Apr; 188(7):524-526. PubMed ID: 26728843
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of triclabendazole (Fasinex) against immature and adult Fasciola hepatica in experimentally infected cattle.
    Shi FH; Lin BF; Qian CG; Li M; Fang MB; Ma JL; Shen W; Wang SW; Jian XL
    Vet Parasitol; 1989 Sep; 33(2):117-24. PubMed ID: 2800300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Distomatosis of the bile ducts. Value of retrograde cholangiography. Efficacy of triclabendazole].
    De Ronde T; Mélange M; Van Beers B; Trigaux JP; Dive C; Lecaillon JB; Poltera AA
    Acta Clin Belg; 1992; 47(3):209-14. PubMed ID: 1332351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of Fasciola hepatica to triclabendazole.
    Overend DJ; Bowen FL
    Aust Vet J; 1995 Jul; 72(7):275-6. PubMed ID: 8534235
    [No Abstract]   [Full Text] [Related]  

  • 18. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole.
    Graham CS; Brodie SB; Weller PF
    Clin Infect Dis; 2001 Jul; 33(1):1-5. PubMed ID: 11389487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US-guided gallbladder aspiration: a new diagnostic method for biliary fascioliasis.
    Kabaalioglu A; Apaydin A; Sindel T; Lüleci E
    Eur Radiol; 1999; 9(5):880-2. PubMed ID: 10369983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle.
    Hutchinson GW; Dawson K; Fitzgibbon CC; Martin PJ
    Vet Parasitol; 2009 Jun; 162(3-4):278-84. PubMed ID: 19375232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.